Track IDEXX Laboratories, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

IDEXX Laboratories, Inc. IDXX · Stock Open IDEXX Laboratories, Inc. in new tab

704.23 USD
P/E
47.04
EPS
14.97
P/B
29.68
ROE
68.93
Beta
1.54
Target Price
717.17 USD
IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc.

🧾 Earnings Recap – Q2 2026

IDEXX outpaced expectations with solid revenue growth and margin expansion, driving a 3.0% stock gain despite headwinds in U.S. clinical visits and a decline in CAG Diagnostics instrument revenues.

  • Q2 organic revenue grew 9%, led by 10.3% organic increase in CAG Diagnostics recurring revenues and 13% growth in Water business.
  • Operating margin expanded 110 basis points, supported by gross margin gains and favorable product costs.
  • EPS rose 15% on a comparable basis to $4.27, with updated full-year EPS guidance raised to $14.69–$14.94.
  • U.S. same-store clinical visits declined 1.3%, primarily due to softness in wellness visits, though non-wellness visits showed modest growth.
  • CAG Diagnostics instrument revenues dropped 20% organically as the company lapped prior-year launches, but instrument placements remained high quality with over 5,200 units placed.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 1, 2027
P/E47.04
EPS14.97
Book Value23.72
Price to Book29.68
Debt/Equity52.05
% Insiders0.675%
Growth
Revenue Growth0.10%
Earnings Growth0.18%
Estimates
Forward P/E41.69
Forward EPS16.89
Target Mean Price717.17

DCF valuation

Model fair value for IDEXX Laboratories, Inc. (IDXX)
Result
Sign in to run the valuation for IDXX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Buy · mean target 717.17 USD (low 470.00, high 810.00) · as of 16 Nov 2026
Low 470.00
Mean 717.17
High 810.00
Price 704.23
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

IDEXX Laboratories, Inc. Logo IDEXX Laboratories, Inc. Analysis (IDXX)

United States Health Care Official Website Stock

Is IDEXX Laboratories, Inc. a good investment? IDEXX Laboratories, Inc. (IDXX) is currently trading at 704.23 USD. Market analysts have a consensus price target of 717.17 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 47.04. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: IDEXX Laboratories, Inc. is expected to release its next earnings report on Feb. 1, 2027. The market consensus estimate for Forward EPS is 16.89.

Investor FAQ

Does IDEXX Laboratories, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is IDEXX Laboratories, Inc.?

IDEXX Laboratories, Inc. is classified as a Stock. You can compare it against 7 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 1, 2027. The company currently has a trailing EPS of 14.97.

Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Exchange Ticker
NMS (United States) IDXX
MEX (Mexico) IDXX.MX
VIE (Austria) IDXX.VI
SAO (Brazil) I1DX34.SA
GER (Germany) IX1.DE
FRA (Germany) IX1.F
LSE (United Kingdom) 0J8P.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 4, 1993 2:1
June 6, 1995 2:1
Nov. 27, 2007 2:1
June 16, 2015 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion